+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Addiction Disorders Drugs Market Research Report by Drug Type (Alcohol, Marijuana, Prescription & Over-the-Counter Medications), Treatment (Counseling & Behavioral Therapies, Detoxification, Medications), End-user - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 135 Pages
  • April 2023
  • Region: United States
  • 360iResearch™
  • ID: 5337784
UP TO OFF until Jun 30th 2023
The United States Addiction Disorders Drugs Market size was estimated at USD 5,124.32 million in 2022, USD 5,580.60 million in 2023 and is projected to grow at a CAGR of 7.08% to reach USD 8,858.83 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Addiction Disorders Drugs Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Addiction Disorders Drugs Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Addiction Disorders Drugs Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Addiction Disorders Drugs Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Addiction Disorders Drugs Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Type, the market is studied across Alcohol, Marijuana, Prescription & Over-the-Counter Medications, Synthetic Cannabinoids, and Tobacco/Nicotine & Vaping.
  • Based on Treatment, the market is studied across Counseling & Behavioral Therapies, Detoxification, Medications, Rehabilitation Programs, and Self-Help Groups.
  • Based on End-user, the market is studied across Hospital & Clinics and Residential Treatment Centers.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Addiction Disorders Drugs Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Addiction Disorders Drugs Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Addiction Disorders Drugs Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Addiction Disorders Drugs Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Addiction Disorders Drugs Market, including Accord Healthcare Limited, Alkermes PLC, Aurobindo Pharma Limited, BioCorRx Inc., Cipla Limited, Consern Pharma Limited, GlaxoSmithKline PLC, Insys Therapeutics, Mallinckrodt Pharmaceuticals, Medtronic PLC, Novartis AG, Perrigo Company PLC, Pfizer, Inc, Psychemedics Corporation, Purdue Pharma L.P., Reckitt Benckiser Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Ltd, and Teva Pharmaceutical Industries, Ltd.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Addiction Disorders Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Addiction Disorders Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Addiction Disorders Drugs Market?
4. What is the competitive strategic window for opportunities in the United States Addiction Disorders Drugs Market?
5. What are the technology trends and regulatory frameworks in the United States Addiction Disorders Drugs Market?
6. What is the market share of the leading vendors in the United States Addiction Disorders Drugs Market?
7. What modes and strategic moves are considered suitable for entering the United States Addiction Disorders Drugs Market?
Frequently Asked Questions about the U.S. Addiction Disorders Drugs Market

What is the estimated value of the U.S. Addiction Disorders Drugs Market?

The U.S. Addiction Disorders Drugs Market was estimated to be valued at $5124.32 Million in 2022.

What is the growth rate of the U.S. Addiction Disorders Drugs Market?

The growth rate of the U.S. Addiction Disorders Drugs Market is 7.0%, with an estimated value of $8858.83 Million by 2030.

What is the forecasted size of the U.S. Addiction Disorders Drugs Market?

The U.S. Addiction Disorders Drugs Market is estimated to be worth $8858.83 Million by 2030.

Who are the key companies in the U.S. Addiction Disorders Drugs Market?

Key companies in the U.S. Addiction Disorders Drugs Market include Accord Healthcare Limited, Alkermes PLC, Aurobindo Pharma Limited, BioCorRx Inc., Cipla Limited, Consern Pharma Limited, GlaxoSmithKline PLC, Insys Therapeutics, Mallinckrodt Pharmaceuticals and Medtronic PLC.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing cases of tobacco and marijuana addiction in the Unitd States
5.1.1.2. Favorable efforts from the governments to curb the use of these substances
5.1.2. Restraints
5.1.2.1. Issues related to product recall
5.1.3. Opportunities
5.1.3.1. Growing introduction of new products and therapy coupled with better reimbursement options
5.1.4. Challenges
5.1.4.1. Multiple side-effects associated with the use of addiction disorders drugs
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization
6. Addiction Disorders Drugs Market, by Drug Type
6.1. Introduction
6.2. Alcohol
6.3. Marijuana
6.4. Prescription & Over-the-Counter Medications
6.5. Synthetic Cannabinoids
6.6. Tobacco/Nicotine & Vaping
7. Addiction Disorders Drugs Market, by Treatment
7.1. Introduction
7.2. Counseling & Behavioral Therapies
7.3. Detoxification
7.4. Medications
7.5. Rehabilitation Programs
7.6. Self-Help Groups
8. Addiction Disorders Drugs Market, by End-user
8.1. Introduction
8.2. Hospital & Clinics
8.3. Residential Treatment Centers
9. California Addiction Disorders Drugs Market
9.1. Introduction
10. Florida Addiction Disorders Drugs Market
10.1. Introduction
11. Illinois Addiction Disorders Drugs Market
11.1. Introduction
12. New York Addiction Disorders Drugs Market
12.1. Introduction
13. Ohio Addiction Disorders Drugs Market
13.1. Introduction
14. Pennsylvania Addiction Disorders Drugs Market
14.1. Introduction
15. Texas Addiction Disorders Drugs Market
15.1. Introduction
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
16.5.1. Merger & Acquisition
16.5.2. Agreement, Collaboration, & Partnership
16.5.3. New Product Launch & Enhancement
16.5.4. Investment & Funding
16.5.5. Award, Recognition, & Expansion
17. Company Usability Profiles
17.1. Accord Healthcare Limited
17.2. Alkermes PLC
17.3. Aurobindo Pharma Limited
17.4. BioCorRx Inc.
17.5. Cipla Limited
17.6. Consern Pharma Limited
17.7. GlaxoSmithKline PLC
17.8. Insys Therapeutics
17.9. Mallinckrodt Pharmaceuticals
17.10. Medtronic PLC
17.11. Novartis AG
17.12. Perrigo Company PLC
17.13. Pfizer, Inc
17.14. Psychemedics Corporation
17.15. Purdue Pharma L.P.
17.16. Reckitt Benckiser Pharmaceuticals, Inc.
17.17. Sun Pharmaceutical Industries Limited
17.18. Takeda Pharmaceutical Company Ltd
17.19. Teva Pharmaceutical Industries, Ltd
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES ADDICTION DISORDERS DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES ADDICTION DISORDERS DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES ADDICTION DISORDERS DRUGS MARKET DYNAMICS
FIGURE 8. UNITED STATES ADDICTION DISORDERS DRUGS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES ADDICTION DISORDERS DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG TYPE, 2030
FIGURE 12. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY MARIJUANA, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION & OVER-THE-COUNTER MEDICATIONS, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SYNTHETIC CANNABINOIDS, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TOBACCO/NICOTINE & VAPING, 2018-2030 (USD MILLION)
FIGURE 17. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ADDICTION DISORDERS DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT, 2030
FIGURE 20. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNSELING & BEHAVIORAL THERAPIES, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DETOXIFICATION, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY REHABILITATION PROGRAMS, 2018-2030 (USD MILLION)
FIGURE 24. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SELF-HELP GROUPS, 2018-2030 (USD MILLION)
FIGURE 25. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 26. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES ADDICTION DISORDERS DRUGS MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USER, 2030
FIGURE 28. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY RESIDENTIAL TREATMENT CENTERS, 2018-2030 (USD MILLION)
FIGURE 30. CALIFORNIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. FLORIDA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. ILLINOIS ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 33. NEW YORK ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 34. OHIO ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. PENNSYLVANIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. TEXAS ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES ADDICTION DISORDERS DRUGS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 38. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 39. UNITED STATES ADDICTION DISORDERS DRUGS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022
List of Tables
TABLE 1. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY MARIJUANA, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY MARIJUANA, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION & OVER-THE-COUNTER MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION & OVER-THE-COUNTER MEDICATIONS, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SYNTHETIC CANNABINOIDS, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SYNTHETIC CANNABINOIDS, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TOBACCO/NICOTINE & VAPING, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TOBACCO/NICOTINE & VAPING, BY STATE, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNSELING & BEHAVIORAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNSELING & BEHAVIORAL THERAPIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DETOXIFICATION, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DETOXIFICATION, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY MEDICATIONS, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY REHABILITATION PROGRAMS, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY REHABILITATION PROGRAMS, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SELF-HELP GROUPS, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY SELF-HELP GROUPS, BY STATE, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY RESIDENTIAL TREATMENT CENTERS, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY RESIDENTIAL TREATMENT CENTERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. CALIFORNIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 33. CALIFORNIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. CALIFORNIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. CALIFORNIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. FLORIDA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 37. FLORIDA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. FLORIDA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. FLORIDA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. ILLINOIS ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 41. ILLINOIS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. ILLINOIS ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. ILLINOIS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. NEW YORK ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 45. NEW YORK ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. NEW YORK ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. NEW YORK ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. OHIO ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. OHIO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. OHIO ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. OHIO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. PENNSYLVANIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. PENNSYLVANIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. PENNSYLVANIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. PENNSYLVANIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. TEXAS ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. TEXAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. TEXAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. TEXAS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ADDICTION DISORDERS DRUGS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 61. UNITED STATES ADDICTION DISORDERS DRUGS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 62. UNITED STATES ADDICTION DISORDERS DRUGS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 63. UNITED STATES ADDICTION DISORDERS DRUGS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 64. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 65. UNITED STATES ADDICTION DISORDERS DRUGS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 66. UNITED STATES ADDICTION DISORDERS DRUGS MARKET MERGER & ACQUISITION
TABLE 67. UNITED STATES ADDICTION DISORDERS DRUGS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 68. UNITED STATES ADDICTION DISORDERS DRUGS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 69. UNITED STATES ADDICTION DISORDERS DRUGS MARKET INVESTMENT & FUNDING
TABLE 70. UNITED STATES ADDICTION DISORDERS DRUGS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 71. UNITED STATES ADDICTION DISORDERS DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

  • Accord Healthcare Limited
  • Alkermes PLC
  • Aurobindo Pharma Limited
  • BioCorRx Inc.
  • Cipla Limited
  • Consern Pharma Limited
  • GlaxoSmithKline PLC
  • Insys Therapeutics
  • Mallinckrodt Pharmaceuticals
  • Medtronic PLC
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer, Inc
  • Psychemedics Corporation
  • Purdue Pharma L.P.
  • Reckitt Benckiser Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries, Ltd

Methodology

Loading
LOADING...